Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Gilead Sciences

Johnson & Johnson

Their products will enjoy strong demand regardless of what happens with the economy.

3 Smart Stocks to Buy if a Recession Is on the Way

AbbVie

Axsome Therapeutics

These companies have what it takes to drive long-term share performance.

3 Unstoppable Stocks to Keep Buying in 2023

Vertex shares are extending last year's gains, and that trend probably isn't over.

5 Reasons to Buy Vertex Pharmaceuticals Now

BOSTON--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call”.

Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7

Moderna

Maravai LifeSciences Holdings

All three are protected by sales of in-demand products, with more on the way.

3 Biopharma Stocks That Could Help Make You a Fortune

Pfizer

Teva Pharmaceutical

Bargains can easily be found as the new year gets underway.

3 Dirt Cheap Stocks to Buy in January

This company's long-term thesis looks impeccable.

1 Top Growth Stock Set to Crush the Market Again in 2023

Shares of Vertex Pharmaceuticals (VRTX) have been in recovery mode since suffering a rapid fall from their Dec. 8 record peak of $324.75.

History Says Bull Should Bet On This Pharma Giant

Amgen

Biogen

BioNTech SE

CSL Ltd

Horizon Pharma

Repligen

The pipeline is the heart of all drug discovery companies, leading to all growth in the future. As such, understanding the relative strength of a pipeline by comparing to peers can lead to investment insights.

Ranking The 10 Largest Biotechs By Pipeline

McKesson

Madrigal Pharmaceuticals

These healthcare stocks have a lot going for them in the new year.

3 Top Healthcare Stocks to Buy for January

Royalty Pharma

Royalty Pharma purchases royalties on pharmaceutical products. Diversification provides some protection for investors and the company has invested in high quality assets.

Royalty Pharma: An Attractive Business Model But An Uncertain Outcome For Vertex's CF Royalties

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Reshma Kewalramani - Chief Executive Officer and President Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Executive Vice President, Global Research, and Chief Scientific Officer Conference Call Participants Jessica Fye - J.P.

Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)

Anavex Life Sciences

Axonics ModulationTechnologies Inc

MannKind

Neurocrine Biosciences

Cassava Sciences Inc

Biotechnology has often been among the most popular sectors in the MoneyShow Top Picks report, our annual survey of the nation's leading newsletter advisors. This year's report is no exception; here's a six-pack of favorite biotech ideas for the coming year.

6 Favorite Biotech Bets For 2023

CRISPR Therapeutics

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years

Etsy

Over time, some of last year's losers could win big.

Looking for Growth in 2023? Where to Invest $5,000

Jazz Pharmaceuticals

These stocks look cheap if you take a long-term view.

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy.

Genmab - ADR

United Therapeutics

Biotech stocks are in high demand right now, with good reason. Indeed, these biotech companies have the potential to revolutionize the medical world and offer solutions to unmet needs, while their relevance is recession-proof.

3 Biotech Companies to Watch in 2023

BOSTON--( BUSINESS WIRE )--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9

Alphabet

MercadoLibre

There's too much to like with these stocks to pass them by.

3 Must-Have Stocks to Buy in 2023

Target

The holidays are over. Let's put our money to work.

Where to Invest $100,000 in 2023

AGNC Investment

Enterprise Products Partners

Fiverr

Mastercard

Markel

NextEra Energy

AT&T

UnitedHealth Group

A new year brings new opportunities for investors to build their wealth on Wall Street.

10 Top Stocks That Can Make You Richer in 2023

Chevron

If money makes the world go round, these three stocks could have it really spinning.

3 Stocks to Buy for 2023 That Are Practically Money Machines

Abbott Labs

Alnylam Pharmaceuticals

argenx

AstraZeneca

Baxter

Bayer AG

BeiGene

Bristol-Myers

United States Brent Oil Fund LP

Invesco DB Oil Fund

Daiichi Sankyo Co Ltd

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

Incyte

Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Oil Stocks And Medicals Shine

News for Vertex Pharmaceuticals Stock (VRTX)